Забуті протозойні тропічні інвазії: стан та перспективи вакцинації на сучасному етапі (огляд літератури)

Автор(и)

  • A. S. Sydorchuk

DOI:

https://doi.org/10.24061/2413-0737.XXI.1.81.2017.47

Ключові слова:

тропічна медицина, вакцинація, «забуті тропічні хвороби», летальність

Анотація

Наведено огляд сучасних даних щодо розробки та імплементації вакцин для специфічної профілактики протозойних «забутих» тропічних хвороб. Висвітлено перспективні напрями створення нових вакцин для специфічної профілактики амебіазу, шкірного та вісцерального лейшманіозу, лямбліозу, криптоспоридіозу.

Посилання

Trykhlib VI. Metodyka prohnozuvannia rivnia zakhvoriuvanosti na maliariiu pid chas perebuvannia v endemichnykh krainakh [A method for predicting the level of malaria incidence when staying in endemic countries]. Sim. med. 2012;3:105-11. (in Ukrainian).

Checkley W, White AC, Jaganath JD. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect. Dis. 2015;15:85-4.

Singh RS, Walia AK, Kanwar JR. Amoebiasis vaccine development: A snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin. Int. J. Biol. Macromol. 2016;91:258-68.

Badaro R. Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 2006;194:1151-159.

Bethony JM, Cole RN, Guo X. Vaccines to combat the neglected tropical diseases. Immunol. Rev. 2011;239:237–70.

Boppana VD, Thangamani S, Adler AJ. SAAG-4 is a novel mosquito salivary protein that programmes host CD4 T cells to express IL-4. Parasite Immunol. 2009;31:287-95.

Easterly W. An ivory tower analysis of real world poverty. The Lancet. 2007;370:1475-476.

Mackey TK, Liang BA, Ryan RC. Emerging and Reemerging Neglected Tropical Diseases: a Review of Key Characteristics, Risk Factors, and the Policy and Innovation Environment. Clin. Microbiol. Rev. 2014;27:949-79.

Benitez A, Priest JW, Ehigiator HN. Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis. Vaccine. 2011;29:9239-245.

Fitzpatrick C, Engels D. Leaving no one behind: a neglected tropical disease indicator and tracers for the Sustainable Development Goals. Int. Health. 2016;8(1):15-8.

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;385:117-71.

Gomes R. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc. Natl. Acad. Sci. USA. 2008;105:7845-850.

Hotez PJ. How To Cure 1 Billion People? Defeat Neglected Tropical diseases. ScientificAmerica. 2010;302(96):90-4.

Hotez PJ. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin. Pharmacol. Ther. 2009;85:659-64.

Anderson KA, Brooks AS, Morrison AL. Impact of Giardia vaccination on asymptomatic Giardia infections in dogs at a research facility.Can.Vet. J. 2004;45:924-30.

McCall LI, Zhang WW, Ranasinghe S. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis. Vaccine. 2013;31:1420-425.

Oliveira F, Lawyer PG, Kamhawi S. Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLoS Negl. Trop. Dis. 2008;2:226.

Bertholet S, Goto Y, Carter L. Optimized subunit vaccine protects against experimental leishmaniasis. Reed Vaccine. 2009;27:7036-45.

O'Connor RM, Burns PB, Ha-Ngoc T. Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro. Eukaryot. Cell. 2009;8:461-69.

Ghenghesh KS, Ghanghish K, BenDarif ET. Prevalence of Entamoeba histolytica, Giardia lamblia, and Cryptosporidium spp. in Libya: 2000-2015. Libyan J. Med. 2016;11:32088.

Rodrigues V, Cordeiro-da-Silva A, Laforge M. Regulation of immunity during visceral Leishmania infection. Parasit. Vectors. 2016;9:118.

Roberts DJ. Hematologic Changes Associated with Specific Infections in the Tropics. Hematol. Oncol. Clin. North Am. 2016;30:395-15.

Morris RV, Shoemaker CB, David JR. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol. 2001;167:5226-230.

Trigo J, Abbehusen M, Netto EM. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine. 2010;28:3333-340.

Tsujimoto H, Gray EW, Champagne DE. Black fly salivary gland extract inhibits proliferation and induces apoptosis in murine splenocytes. Parasite Immunol. 2010;32:275-84.

Bethony JM, Cole RN, Guo X. Vaccines to combat the neglected tropical diseases. Immunol. Rev. 2011;239:237-70.

Vinhas V. Human anti-saliva immune response following experimental exposure to the visceral leishmaniasis vector, Lutzomyia longipalpis. Eur. J. Immunol. 2007;37:3111-121.

Jenikova G, Hruz P, Andersson KM. α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. Vaccine. 2011;29:9529-537.

##submission.downloads##

Опубліковано

2017-02-23

Номер

Розділ

НАУКОВІ ОГЛЯДИ